SCIENTIFIC HUB

Follow the evidence.

SCIENTIFIC LITERATURE · MED

Case Report: Neonatal-onset parkinsonian-pyramidal syndrome caused by novel compound heterozygous <i>FBXO7</i> variants.

Front Pediatr · 2026-09-17

DOI: 10.3389/fped.2026.1934625PMID: 42824211

Open accessJournal Article; Case Reports; case-reportOriginal source ↗

Research overview

The text below is the source article’s original abstract under a verified reuse license. cc by

BackgroundEarly-onset parkinsonism is often associated with genetic factors. Pathogenic variants in the FBXO7 gene are a rare cause of early-onset parkinsonism, typically presenting as parkinsonian-pyramidal syndrome (PPS), also known as Parkinson's disease-15 (PARK15). To date, only three cases of infantile-onset PARK15 have been reported worldwide. Herein, we describe a Chinese patient with neonatal-onset PARK15, who carried novel compound heterozygous FBXO7 variants.Case presentationA 37-hour-old male infant with generalized limb rigidity was referred for evaluation of neonatal-onset hypertonia. Physical examination revealed abnormal vocalization, poor sucking and swallowing (requiring nasogastric tube feeding), and abdominal muscle rigidity. Pyramidal involvement was evidenced by positive Babinski sign and its equivalents, together with hyperreflexia, while extrapyramidal findings included lead-pipe rigidity of all four limbs with markedly increased muscle tone. Whole-exome sequencing identified two compound heterozygous nonsense variants in FBXO7, c.376G > T (p.Gly126*) and c.1033C > T (p.Arg345*), inherited from the father and mother, respectively. Both variants were classified as pathogenic. Following diagnosis, the parents elected to discontinue active in-hospital treatment, and the infant was discharged home. Nevertheless, a trial of oral levodopa was initiated at home. Despite levodopa treatment, the infant showed no clinical improvement and died at 89 days of age.ConclusionsTo our knowledge, this is the first reported case of neonatal-onset PARK15 caused by FBXO7 variants. This case expands the mutational and clinical spectrum of PARK15 in the neonatal period.

Scientific assessment

01

Research question

Assess the question within the original study’s scope.

02

Methods & sample

Check the source article for study design and sample details.

03

Key findings

An editorially approved findings summary is not yet published for this record.

04

Limitations

Generalizability, bias and clinical meaning require separate assessment.

Methods, samples and clinical conclusions are not inferred from bibliographic metadata.